MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by ...

In the past twenty years, major technological advances in extracting and analyzing DNA have transformed the ability to ...

First and only company with 100 approved and active companion diagnostic indications for next-generation sequencing in the ...

Comparing proteomics to genomics reveals essential insights into their contributions to systems biology and experimental ...

NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in ...

JAK2 gene fusion appears across multiple CTCL types, shaping diagnosis and treatment opportunities. Learn more about its ...

Ansa Biotechnologies Inc., the trusted partner for DNA synthesis, today announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer. Mr. Hamilton will report ...

In a wide-ranging discussion on the future of genomics and cancer diagnostics in India, senior leaders from Strand Life ...

The Derisq AI Report uses GATC Health’s proprietary AI platform to provide biopharma leaders and investors with an objective, data-driven assessment of a drug candidate’s likely endpoint ...

Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...